{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:17:41Z","timestamp":1789388261559,"version":"build-2803163510"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2016,4,4]],"date-time":"2016-04-04T00:00:00Z","timestamp":1459728000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s00432-016-2144-1","type":"journal-article","created":{"date-parts":[[2016,4,4]],"date-time":"2016-04-04T14:53:55Z","timestamp":1459781635000},"page":"2013-2022","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Hematologic malignancies: newer strategies to counter the BCL-2 protein"],"prefix":"10.1007","volume":"142","author":[{"given":"Abdul Shukkur","family":"Ebrahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussam","family":"Sabbagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Liddane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Raufi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustapha","family":"Kandouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5684-948X","authenticated-orcid":false,"given":"Ayad","family":"Al-Katib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,4]]},"reference":[{"issue":"1","key":"2144_CR1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2001-1326-2-3","volume":"2","author":"LN Abdullah","year":"2013","unstructured":"Abdullah LN, Chow EK-H (2013) Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med 2(1):3","journal-title":"Clin Transl Med"},{"issue":"10","key":"2144_CR2","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1158\/1535-7163.MCT-08-0268","volume":"7","author":"S Ackler","year":"2008","unstructured":"Ackler S, Xiao Y, Mitten MJ, Foster K, Oleksijew A, Refici M, Bauch J (2008) ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Mol Cancer Ther 7(10):3265\u20133274","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"2144_CR3","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/MMBR.67.4.657-685.2003","volume":"67","author":"N Agrawal","year":"2003","unstructured":"Agrawal N, Dasaradhi P, Mohmmed A, Malhotra P, Bhatnagar RK, Mukherjee SK (2003) RNA interference: biology, mechanism, and applications. Microbiol Mol Biol Rev 67(4):657\u2013685","journal-title":"Microbiol Mol Biol Rev"},{"key":"2144_CR4","doi-asserted-by":"crossref","unstructured":"Al-Katib AM, Sun Y, Goustin AS, Azmi AS, Chen B, Aboukameel A, Mohammad RM (2009). SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status. J Hematol Oncol 2(8)","DOI":"10.1186\/1756-8722-2-8"},{"key":"2144_CR5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1476-4598-7-20","volume":"7","author":"AA Arnold","year":"2008","unstructured":"Arnold AA, Aboukameel A, Chen J, Yang D, Wang S, Al-Katib A, Mohammad RM (2008) Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-X. Mol Cancer 7:20","journal-title":"Mol Cancer"},{"issue":"51","key":"2144_CR6","doi-asserted-by":"crossref","first-page":"42502","DOI":"10.1074\/jbc.M112.365163","volume":"287","author":"A Banerjee","year":"2012","unstructured":"Banerjee A, Qian P, Wu Z-S, Ren X, Steiner M, Bougen NM, Lobie PE (2012) Artemin stimulates radio- and chemo-resistance by promoting TWIST1-BCL-2-dependent cancer stem cell-like behavior in mammary carcinoma cells. J Biol Chem 287(51):42502\u201342515","journal-title":"J Biol Chem"},{"key":"2144_CR7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","volume":"50","author":"CF Bennett","year":"2010","unstructured":"Bennett CF, Swayze EE (2010) RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 50:259\u2013293","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"6","key":"2144_CR8","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/CCO.0000000000000127","volume":"26","author":"D Castanotto","year":"2014","unstructured":"Castanotto D, Stein CA (2014) Antisense oligonucleotides in cancer. Curr Opin Oncol 26(6):584\u2013589","journal-title":"Curr Opin Oncol"},{"issue":"4","key":"2144_CR9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.tcb.2008.01.007","volume":"18","author":"JE Chipuk","year":"2008","unstructured":"Chipuk JE, Green DR (2008) How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol 18(4):157\u2013164","journal-title":"Trends Cell Biol"},{"issue":"1","key":"2144_CR10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0092-8674(86)90362-4","volume":"47","author":"ML Cleary","year":"1986","unstructured":"Cleary ML, Smith SD, Sklar J (1986) Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2\/immunoglobulin transcript resulting from the t(14; 18) translocation. Cell 47(1):19\u201328","journal-title":"Cell"},{"issue":"9","key":"2144_CR11","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1080\/10428190600725354","volume":"47","author":"G Congmin","year":"2006","unstructured":"Congmin G, Mu Z, Yihui M, Hanliang L (2006) Survivin-an attractive target for RNAi in non-Hodgkin\u2019s lymphoma, Daudi cell line as a model. Leuk Lymphoma 47(9):1941\u20131948","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2144_CR12","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nrc883","volume":"2","author":"S Cory","year":"2002","unstructured":"Cory S, Adams JM (2002) The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2(9):647\u2013656","journal-title":"Nat Rev Cancer"},{"issue":"21","key":"2144_CR13","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood.V122.21.1789.1789","volume":"122","author":"MS Davids","year":"2013","unstructured":"Davids MS, Pagel JM, Kahl BS, Wierda WG, Miller TP, Gerecitano JF, Rudersdorf NK (2013) Bcl-2 inhibitor ABT-199 (GDC-0199) monotherapy shows anti-tumor activity including complete remissions in high-risk relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Blood 122(21):872","journal-title":"Blood"},{"issue":"5","key":"2144_CR14","first-page":"347","volume":"1","author":"N Dias","year":"2002","unstructured":"Dias N, Stein C (2002) Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 1(5):347\u2013355","journal-title":"Mol Cancer Ther"},{"issue":"20","key":"2144_CR15","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa1308392","volume":"369","author":"K Dunleavy","year":"2013","unstructured":"Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C, Little RF (2013) Low-intensity therapy in adults with Burkitt\u2019s lymphoma. N Engl J Med 369(20):1915\u20131925","journal-title":"N Engl J Med"},{"key":"2144_CR01","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.addr.2015.03.008","volume":"87","author":"MM Evers","year":"2015","unstructured":"Evers MM, Toonen LJ, van Roon-Mom WM (2015) Antisense oligonucleotides in therapy for neurodegenerative disorders. Adv Drug Deliv Rev 87:90\u2013103","journal-title":"Adv Drug Deliv Rev"},{"key":"2144_CR16","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.2147\/OTT.S49652","volume":"7","author":"AA Farooqi","year":"2014","unstructured":"Farooqi AA, Rehman ZU, Muntane J (2014) Antisense therapeutics in oncology: current status. Onco Targets Ther 7:2035","journal-title":"Onco Targets Ther"},{"issue":"6669","key":"2144_CR17","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","volume":"391","author":"A Fire","year":"1998","unstructured":"Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391(6669):806\u2013811","journal-title":"Nature"},{"issue":"11","key":"2144_CR18","doi-asserted-by":"crossref","first-page":"5723","DOI":"10.1073\/pnas.97.11.5723","volume":"97","author":"R Foyouzi-Youssefi","year":"2000","unstructured":"Foyouzi-Youssefi R, Arnaudeau S, Borner C, Kelley WL, Tschopp J, Lew DP, Krause K-H (2000) Bcl-2 decreases the free Ca2\u00a0+\u00a0concentration within the endoplasmic reticulum. Proc Natl Acad Sci 97(11):5723\u20135728","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"2144_CR19","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1021\/bc034084n","volume":"14","author":"F Gallazzi","year":"2003","unstructured":"Gallazzi F, Wang Y, Jia F, Shenoy N, Landon LA, Hannink M, Lewis MR (2003) Synthesis of radiometal-labeled and fluorescent cell-permeating peptide-PNA conjugates for targeting the bcl-2 proto-oncogene. Bioconjug Chem 14(6):1083\u20131095","journal-title":"Bioconjug Chem"},{"issue":"1","key":"2144_CR20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/cdd.2014.137","volume":"22","author":"L Galluzzi","year":"2015","unstructured":"Galluzzi L, Bravo-San Pedro J, Vitale I, Aaronson S, Abrams J, Adam D, Annicchiarico-Petruzzelli M (2015) Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ 22(1):58\u201373","journal-title":"Cell Death Differ"},{"issue":"7","key":"2144_CR21","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2010.31.6208","volume":"29","author":"L Gandhi","year":"2011","unstructured":"Gandhi L, Camidge DR, de Oliveira MR, Bonomi P, Gandara D, Khaira D, Hemken PM (2011) Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 29(7):909\u2013916","journal-title":"J Clin Oncol"},{"key":"2144_CR22","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/978-3-319-17121-0_69","volume":"854","author":"X Gerard","year":"2016","unstructured":"Gerard X, Garanto A, Rozet J-M, Collin RW (2016) Antisense oligonucleotide therapy for inherited retinal dystrophies. Retin Degener Dis 854:517\u2013524","journal-title":"Retin Degener Dis"},{"issue":"4","key":"2144_CR23","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/jcb.24709","volume":"115","author":"LA Gillies","year":"2014","unstructured":"Gillies LA, Kuwana T (2014) Apoptosis regulation at the mitochondrial outer membrane. J Cell Biochem 115(4):632\u2013640","journal-title":"J Cell Biochem"},{"key":"2144_CR24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/CE.S42568","volume":"8","author":"CA Goard","year":"2013","unstructured":"Goard CA, Schimmer AD (2013) An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies. Core Evid 8:15","journal-title":"Core Evid"},{"key":"2144_CR25","doi-asserted-by":"crossref","unstructured":"Harb W, Lakhani N, Logsdon A, Steigelman M, Smith-Green H, Gaylor S et al (2014) The BCL2 targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 is active in patients with relapsed or refractory non-Hodgkin\u2019s lymphoma. Paper presented at the American Society of hematology annual meeting","DOI":"10.1182\/blood.V124.21.1716.1716"},{"issue":"12","key":"2144_CR26","doi-asserted-by":"crossref","first-page":"4245s","DOI":"10.1158\/1078-0432.CCR-040018","volume":"10","author":"RS Herbst","year":"2004","unstructured":"Herbst RS, Frankel SR (2004) Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide) a rational therapeutic to enhance apoptosis in therapy of lung cancer. Clin Cancer Res 10(12):4245s\u20134248s","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2144_CR27","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/sj.cgt.7700791","volume":"12","author":"M Izquierdo","year":"2005","unstructured":"Izquierdo M (2005) Short interfering RNAs as a tool for cancer gene therapy. Cancer Gene Ther 12(3):217\u2013227","journal-title":"Cancer Gene Ther"},{"issue":"8","key":"2144_CR28","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/BF02663050","volume":"56","author":"LA Jones","year":"1979","unstructured":"Jones LA (1979) Gossypol and some other terpenoids, flavonoids, and phenols that affect quality of cottonseed protein. J Am Oil Chem Soc 56(8):727\u2013730","journal-title":"J Am Oil Chem Soc"},{"issue":"4","key":"2144_CR29","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1158\/1078-0432.CCR-08-0144","volume":"15","author":"MH Kang","year":"2009","unstructured":"Kang MH, Reynolds CP (2009) Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 15(4):1126\u20131132","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2144_CR30","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/cdd.2012.92","volume":"20","author":"P Kelly","year":"2013","unstructured":"Kelly P, Grabow S, Delbridge A, Adams J, Strasser A (2013) Prophylactic treatment with the BH3 mimetic ABT-737 impedes Myc-driven lymphomagenesis in mice. Cell Death Differ 20(1):57\u201363","journal-title":"Cell Death Differ"},{"issue":"2","key":"2144_CR31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.bbamcr.2003.08.009","volume":"1644","author":"V Kirkin","year":"2004","unstructured":"Kirkin V, Joos S, Z\u00f6rnig M (2004) The role of Bcl-2 family members in tumorigenesis. Biochimica et Biophysica Acta (BBA)-Mol Cell Res 1644(2):229\u2013249","journal-title":"Biochimica et Biophysica Acta (BBA)-Mol Cell Res"},{"issue":"6","key":"2144_CR32","first-page":"2492","volume":"6","author":"RJ Klasa","year":"2000","unstructured":"Klasa RJ, Bally MB, Ng R, Goldie JH, Gascoyne RD, Wong FM (2000) Eradication of human non-Hodgkin\u2019s lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin Cancer Res 6(6):2492\u20132500","journal-title":"Clin Cancer Res"},{"key":"2144_CR33","unstructured":"Large B-Cell Lymphoma. In: ClinicalTrials.gov. National Library of Medicine (US), Bethesda. 2000-(cited 2015 Dec 4). https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02226965 . NLM Identifier:NCT02226965"},{"issue":"9","key":"2144_CR34","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.nucmedbio.2015.05.006","volume":"42","author":"D Liu","year":"2015","unstructured":"Liu D, Balkin ER, Jia F, Ruthengael VC, Smith CJ, Lewis MR (2015) Targeted antisense radiotherapy and dose fractionation using a 177 Lu-labeled anti-bcl-2 peptide nucleic acid-peptide conjugate. Nucl Med Biol\u00a042(9):704\u2013710","journal-title":"Nucl Med Biol"},{"issue":"9","key":"2144_CR35","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1177\/1535370213498985","volume":"238","author":"SA Maxwell","year":"2013","unstructured":"Maxwell SA, Mousavi-Fard S (2013). Non-Hodgkin\u2019s B-cell lymphoma: advances in molecular strategies targeting drug resistance. Exp Biol Med\u00a0238(9):971\u2013990","journal-title":"Exp Biol Med"},{"issue":"12","key":"2144_CR36","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1158\/0008-5472.CAN-11-4106","volume":"72","author":"S Mazumder","year":"2012","unstructured":"Mazumder S, Choudhary GS, Al-harbi S, Almasan A (2012) Mcl-1 phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells. Cancer Res 72(12):3069\u20133079","journal-title":"Cancer Res"},{"issue":"5","key":"2144_CR37","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.V86.5.1903.bloodjournal8651903","volume":"86","author":"A Minn","year":"1995","unstructured":"Minn A, Rudin CM, Boise LH, Thompson CB (1995) Expression of bcl-xL can confer a multidrug resistance phenotype. Blood 86(5):1903\u20131910","journal-title":"Blood"},{"issue":"1","key":"2144_CR38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1158\/1535-7163.13.4.1","volume":"4","author":"RM Mohammad","year":"2005","unstructured":"Mohammad RM, Wang S, Aboukameel A, Chen B, Wu X, Chen J, Al-Katib A (2005) Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-XL [(\u2212)-gossypol] against diffuse large cell lymphoma. Mol Cancer Ther 4(1):13\u201321","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"2144_CR39","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1006\/bbrc.1999.1548","volume":"264","author":"L Mologni","year":"1999","unstructured":"Mologni L, Nielsen PE, Gambacorti-Passerini C (1999) In vitro transcriptional and translational block of the bcl-2 gene operated by peptide nucleic acid. Biochem Biophys Res Commun 264(2):537\u2013543","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"2144_CR40","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.canlet.2011.12.021","volume":"332","author":"VDG Moore","year":"2013","unstructured":"Moore VDG, Letai A (2013) BH3 profiling-measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett 332(2):202\u2013205","journal-title":"Cancer Lett"},{"issue":"3","key":"2144_CR41","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1385\/MB:26:3:233","volume":"26","author":"PE Nielsen","year":"2004","unstructured":"Nielsen PE (2004) PNA technology. Mol Biotechnol 26(3):233\u2013248","journal-title":"Mol Biotechnol"},{"issue":"2","key":"2144_CR42","first-page":"184","volume":"12","author":"PE Nielsen","year":"2010","unstructured":"Nielsen PE (2010) Sequence-selective targeting of duplex DNA by peptide nucleic acids. Curr Opin Mol Ther 12(2):184\u2013191","journal-title":"Curr Opin Mol Ther"},{"issue":"9","key":"2144_CR43","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1182\/blood-2011-11-391037","volume":"119","author":"Y Oki","year":"2012","unstructured":"Oki Y, Copeland A, Hagemeister F, Fayad LE, Fanale M, Romaguera J, Younes A (2012) Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma. Blood 119(9):2171\u20132172","journal-title":"Blood"},{"issue":"7042","key":"2144_CR44","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","volume":"435","author":"T Oltersdorf","year":"2005","unstructured":"Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Hajduk PJ (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435(7042):677\u2013681","journal-title":"Nature"},{"issue":"4","key":"2144_CR45","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2567.2005.02117.x","volume":"114","author":"G Packham","year":"2005","unstructured":"Packham G, Stevenson FK (2005) Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia. Immunology 114(4):441\u2013449","journal-title":"Immunology"},{"issue":"12","key":"2144_CR46","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/nm1134","volume":"10","author":"JM Polo","year":"2004","unstructured":"Polo JM, Dell\u2019Oso T, Ranuncolo SM, Cerchietti L, Beck D, Da Silva GF, Melnick A (2004) Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med 10(12):1329\u20131335","journal-title":"Nat Med"},{"issue":"3","key":"2144_CR47","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2008.07353.x","volume":"143","author":"B Pro","year":"2008","unstructured":"Pro B, Leber B, Smith M, Fayad L, Romaguera J, Hagemeister F, Zwiebel J (2008) Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br J Haematol 143(3):355\u2013360","journal-title":"Br J Haematol"},{"key":"2144_CR48","unstructured":"Profile AR (2002) Augmerosen, Bcl-2 antisense oligonucleotide-genta, GC 3139, Genasense"},{"key":"2144_CR49","unstructured":"ProNAi Therapeutics, Inc. A Phase II study of PNT2258 in patients with relapse or refractory diffuse"},{"issue":"7","key":"2144_CR50","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2007-09-078162","volume":"111","author":"JC Reed","year":"2008","unstructured":"Reed JC (2008) Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood 111(7):3322\u20133330","journal-title":"Blood"},{"issue":"2","key":"2144_CR51","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1182\/blood-2004-07-2761","volume":"106","author":"JC Reed","year":"2005","unstructured":"Reed JC, Pellecchia M (2005) Apoptosis-based therapies for hematologic malignancies. Blood 106(2):408\u2013418","journal-title":"Blood"},{"key":"2144_CR52","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/978-1-4613-1261-1_3","volume":"84","author":"JC Reed","year":"1996","unstructured":"Reed JC, Miyashita T, Krajewski S, Takayama S, Aime-Sempe C, Kitada S et al (1996) Bcl-2 family proteins and the regulation of programmed cell death in leukemia and lymphoma. Mol Genet Ther Leuk 84:31\u201372","journal-title":"Mol Genet Ther Leuk"},{"key":"2144_CR53","doi-asserted-by":"crossref","unstructured":"Roberts A, Gandhi L, O\u2019Connor O, Rudin C, Khaira D, Xiong H et al (2008) Reduction in platelet counts as a mechanistic biomarker and guide for adaptive dose-escalation in phase I studies of the Bcl-2 family inhibitor ABT-263. Paper presented at the ASCO annual meeting proceedings","DOI":"10.1200\/jco.2008.26.15_suppl.3542"},{"issue":"1","key":"2144_CR54","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00280-014-2476-y","volume":"74","author":"WV Rodrigueza","year":"2014","unstructured":"Rodrigueza WV, Woolliscroft MJ, Ebrahim A-S, Forgey R, McGovren PJ, Endert G, Gill RD (2014) Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide. Cancer Chemother Pharmacol 74(1):151\u2013166","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"2144_CR55","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s13277-010-0133-6","volume":"32","author":"Y Sagawa","year":"2011","unstructured":"Sagawa Y, Fujitoh A, Nishi H, Ito H, Yudate T, Isaka K (2011) Establishment of three cisplatin-resistant endometrial cancer cell lines using two methods of cisplatin exposure. Tumor Biol 32(2):399\u2013408","journal-title":"Tumor Biol"},{"issue":"3","key":"2144_CR56","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/leu.2013.361","volume":"28","author":"M Scherr","year":"2014","unstructured":"Scherr M, Elder A, Battmer K, Barzan D, Bomken S, Ricke-Hoch M, Vormoor J (2014) Differential expression of miR-17\u00a0\u223c\u00a092 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia. Leukemia 28(3):554\u2013565","journal-title":"Leukemia"},{"key":"2144_CR57","doi-asserted-by":"crossref","unstructured":"Sheikhnejad R (2009) MicroDNAs (MIDs) and transcriptional regulation. Nature Precedings http:\/\/hdl.handle.net\/10101\/npre.2009.3931.1","DOI":"10.1038\/npre.2009.3931.1"},{"key":"2144_CR58","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4939-1538-5","volume-title":"RNA interference: mechanisms, technical challenges, and therapeutic opportunities","author":"M Sioud","year":"2015","unstructured":"Sioud M (2015) RNA interference: mechanisms, technical challenges, and therapeutic opportunities. Springer, Berlin"},{"issue":"2","key":"2144_CR59","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Fairbrother WJ (2013) ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19(2):202\u2013208","journal-title":"Nat Med"},{"issue":"2","key":"2144_CR60","first-page":"313","volume":"34","author":"Y Tabuchi","year":"2009","unstructured":"Tabuchi Y, Matsuoka J, Gunduz M, Imada T, Ono R, Ito M, Takaoka M (2009) Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer. Int J Oncol 34(2):313\u2013319","journal-title":"Int J Oncol"},{"issue":"1","key":"2144_CR61","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1517\/14728222.2013.733001","volume":"17","author":"S Thomas","year":"2013","unstructured":"Thomas S, Quinn BA, Das SK, Dash R, Emdad L, Dasgupta S, Pellecchia M (2013) Targeting the Bcl-2 family for cancer therapy. Expert Opin Ther Targets 17(1):61\u201375","journal-title":"Expert Opin Ther Targets"},{"issue":"8","key":"2144_CR62","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.1074\/jbc.M208878200","volume":"278","author":"MJ Thomenius","year":"2003","unstructured":"Thomenius MJ, Wang NS, Reineks EZ, Wang Z, Distelhorst CW (2003) Bcl-2 on the endoplasmic reticulum regulates Bax activity by binding to BH3-only proteins. J Biol Chem 278(8):6243\u20136250","journal-title":"J Biol Chem"},{"issue":"2","key":"2144_CR63","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00280-013-2361-0","volume":"73","author":"AW Tolcher","year":"2014","unstructured":"Tolcher AW, Rodrigueza WV, Rasco DW, Patnaik A, Papadopoulos KP, Amaya A, Sooch MP (2014) A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors. Cancer Chemother Pharmacol 73(2):363\u2013371","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"2144_CR64","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","volume":"68","author":"C Tse","year":"2008","unstructured":"Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Nimmer P (2008) ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68(9):3421\u20133428","journal-title":"Cancer Res"},{"issue":"11","key":"2144_CR65","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1046\/j.1365-2443.1998.00223.x","volume":"3","author":"Y Tsujimoto","year":"1998","unstructured":"Tsujimoto Y (1998) Role of Bcl-2 family proteins in apoptosis: apoptosomes or mitochondria? Genes Cells 3(11):697\u2013707","journal-title":"Genes Cells"},{"issue":"4678","key":"2144_CR66","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.6093263","volume":"226","author":"Y Tsujimoto","year":"1984","unstructured":"Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM (1984) Cloning of the chromosome breakpoint of neoplastic B cells with the t (14; 18) chromosome translocation. Science 226(4678):1097\u20131099","journal-title":"Science"},{"issue":"4","key":"2144_CR67","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1158\/1535-7163.MCT-07-0302","volume":"7","author":"CA Tucker","year":"2008","unstructured":"Tucker CA, Kapanen AI, Chikh G, Hoffman BG, Kyle AH, Wilson IM, Klasa RJ (2008) Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-\u03baB, p53, bax, and p27 levels. Mol Cancer Ther 7(4):749\u2013758","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"2144_CR68","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1182\/blood-2013-01-475855","volume":"121","author":"CJ Vandenberg","year":"2013","unstructured":"Vandenberg CJ, Cory S (2013) ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood 121(12):2285\u20132288","journal-title":"Blood"},{"issue":"10","key":"2144_CR69","doi-asserted-by":"crossref","first-page":"e108625","DOI":"10.1371\/journal.pone.0108625","volume":"9","author":"TA Vickers","year":"2014","unstructured":"Vickers TA, Crooke ST (2014) Antisense oligonucleotides capable of promoting specific target mRNA reduction via competing RNase H1-dependent and independent mechanisms. PloS one 9(10):e108625","journal-title":"PloS one"},{"issue":"21","key":"2144_CR70","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.1021\/jm060460o","volume":"49","author":"G Wang","year":"2006","unstructured":"Wang G, Nikolovska-Coleska Z, Yang C-Y, Wang R, Tang G, Guo J, Yang D (2006) Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem 49(21):6139\u20136142","journal-title":"J Med Chem"},{"issue":"2","key":"2144_CR71","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/path.2993","volume":"226","author":"JK Watts","year":"2012","unstructured":"Watts JK, Corey DR (2012) Silencing disease genes in the laboratory and the clinic. J Pathol 226(2):365\u2013379","journal-title":"J Pathol"},{"issue":"9","key":"2144_CR72","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1517\/17460441.3.9.1123","volume":"3","author":"MD Wendt","year":"2008","unstructured":"Wendt MD (2008) Discovery of ABT-263, a Bcl-family protein inhibitor: observations on targeting a large protein\u2013protein interaction. Expert Opin Drug Discov 3(9):1123\u20131143","journal-title":"Expert Opin Drug Discov"},{"issue":"17","key":"2144_CR73","doi-asserted-by":"crossref","first-page":"17181","DOI":"10.1074\/jbc.M311683200","volume":"279","author":"H Wu","year":"2004","unstructured":"Wu H, Lima WF, Zhang H, Fan A, Sun H, Crooke ST (2004) Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J Biol Chem 279(17):17181\u201317189","journal-title":"J Biol Chem"},{"issue":"12","key":"2144_CR74","first-page":"1288","volume":"21","author":"X Yang","year":"2002","unstructured":"Yang X, Zheng F, Chen J, Gao Q, Lu Y, Wang S, Ma D (2002) Relationship between expression of apoptosis-associated proteins and caspase-3 activity in cisplatin-resistant human ovarian cancer cell line. Ai Zheng 21(12):1288\u20131291","journal-title":"Ai Zheng"},{"issue":"8","key":"2144_CR75","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/sj.cdd.4401937","volume":"13","author":"D Zhai","year":"2006","unstructured":"Zhai D, Jin C, Satterthwait A, Reed J (2006) Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ 13(8):1419\u20131421","journal-title":"Cell Death Differ"},{"issue":"9 Supplement","key":"2144_CR76","first-page":"5182","volume":"67","author":"Y Zhang","year":"2007","unstructured":"Zhang Y, Lin Y, Min P, Zhang X, Ling X, Guo M, Yang D (2007) A novel pan inhibitor of Bcl-2 and Mcl-1 apogossypolone (ApoG2) with superior stability and improved activity against human leukemia and lymphoma cells. Cancer Res 67(9 Supplement):5182","journal-title":"Cancer Res"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-016-2144-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-016-2144-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-016-2144-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T01:23:19Z","timestamp":1655428999000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-016-2144-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,4]]},"references-count":77,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["2144"],"URL":"https:\/\/doi.org\/10.1007\/s00432-016-2144-1","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,4]]}}}